Provided by Tiger Trade Technology Pte. Ltd.

Rigel Pharmaceuticals

45.11
-0.7800-1.70%
Post-market: 45.110.00000.00%19:58 EDT
Volume:542.01K
Turnover:24.54M
Market Cap:842.65M
PE:2.74
High:46.21
Open:45.63
Low:44.51
Close:45.89
52wk High:52.24
52wk Low:24.95
Shares:18.68M
Float Shares:14.85M
Volume Ratio:1.34
T/O Rate:3.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):16.45
EPS(LYR):19.48
ROE:126.90%
ROA:14.95%
PB:1.98
PE(LYR):2.32

Loading ...

Rigel Pharmaceuticals Q1 EPS $0.44 Misses $0.76 Estimate, Sales $58.800M Miss $62.392M Estimate

Benzinga Earnings
·
May 06

Rigel Pharmaceuticals Inc: Reaffirms Its 2026 Total Revenues Guidance

THOMSON REUTERS
·
May 06

Rigel Pharmaceuticals: Continues to Anticipate It Will Report Positive Net Income for Full Year 2026

THOMSON REUTERS
·
May 06

Rigel Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 06

Rigel Pharmaceuticals Q1 Revenue USD 58.8 Million VS. Ibes Estimate USD 62.4 Million

THOMSON REUTERS
·
May 06

Rigel Pharmaceuticals Q1 EPS USD 0.44

THOMSON REUTERS
·
May 06

BRIEF-Kissei Pharmaceutical Co Ltd - Licensing Agreement For "Olutasidenib" With Orient Europharma In Taiwan

Reuters
·
May 01

Kissei Pharmaceutical Co Ltd: Kissei Will Receive an Upfront Payment and Milestone Payments Based on Progress of Commercialization in Taiwan, and Will Supply Formulation to Oep

THOMSON REUTERS
·
May 01

Kissei Pharmaceutical Co Ltd: Licensing Agreement for "Olutasidenib" With Orient Europharma in Taiwan

THOMSON REUTERS
·
May 01

Rigel to report first-quarter results, host conference call and webcast

Reuters
·
Apr 28

BRIEF-Rigel Pharmaceuticals Inc On April 16, Received Written Notice From Eli Lilly

Reuters
·
Apr 22

Rigel Regains Rights as Eli Lilly Ends Collaboration

TIPRANKS
·
Apr 22

Rigel Pharmaceuticals Inc - Does Not Expect Future Milestones or Royalties Under Agreement After Termination - SEC Filing

THOMSON REUTERS
·
Apr 22

Rigel grants 8,925 inducement RSUs to six new employees under NASDAQ rule 5635(c)(4)

Reuters
·
Apr 07

Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 07

Rigel Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 04

Rigel Pharmaceuticals Balances Breakout Growth With Caution

TIPRANKS
·
Apr 02

Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC

Reuters
·
Apr 01

BRIEF-Rigel Announces Publication Of Final Arrow Clinical Trial Data On Gavreto® (Pralsetinib)

Reuters
·
Mar 31

Rigel Announces Publication of Final Arrow Clinical Trial Data on Gavreto® (Pralsetinib) in Patients With Ret+ Nsclc in the Journal of Clinical Oncology

THOMSON REUTERS
·
Mar 31